{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:52:02Z","timestamp":1782143522915,"version":"3.54.5"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mirikizumab, a selective IL-23p19 monoclonal antibody, has demonstrated efficacy in moderate-to-severe ulcerative colitis (UC) although real-world data are limited. In addition, registrational trials excluded patients previously treated with ustekinumab, which targets the IL-12\/23 p40 subunit.<\/jats:p>\n                    <jats:p>We aimed to evaluate the real-world effectiveness and safety of mirikizumab in a multicentre UK cohort of patients with UC, including those with prior ustekinumab exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study was conducted across three tertiary UK centres. Adults with confirmed UC who received mirikizumab and had \u226512 weeks of follow-up were included. Data on demographics, disease activity (SCCAI, UCEIS), biomarkers (CRP, faecal calprotectin), and treatment persistence were analysed at 3 and 6 months. Outcomes were compared between ustekinumab-exposed and -na\u00efve patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 100 patients (36 ustekinumab-exposed), treatment persistence at 3 months was 72% with no significant difference between groups. SCCAI scores decreased from 5.8 to 3.3 at 3 months (p\u2009&amp;lt;\u20090.00001), and faecal calprotectin decreased from 1094 \u00b5g\/g to 586 \u00b5g\/g (p\u2009=\u20090.006). UCEIS scores (n\u2009=\u200936) improved significantly post-induction (mean 4.4 to 2.7, p\u2009&amp;lt;\u20090.000001). Multivariable logistic regression did not reveal any factors associated with<\/jats:p>\n                    <jats:p>treatment persistence, including prior ustekinumab exposure. Adverse events were infrequent and mild.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Mirikizumab is effective and well tolerated in a real-world UC population, including patients with prior ustekinumab exposure. These findings support the use of IL-23p19 inhibition regardless of previous IL-12\/23 blockade.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag065","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:47:32Z","timestamp":1781783252000},"source":"Crossref","is-referenced-by-count":0,"title":["Mirikizumab is Equally Effective in Ustekinumab-Exposed and Ustekinumab-Na\u00efve Patients with UC: A Multicentre Real-World Cohort"],"prefix":"10.1093","author":[{"given":"Mohmmed Tauseef","family":"Sharip","sequence":"first","affiliation":[{"name":"Cambridge University Hospital NHS Trust , Cambridge,","place":["UK"]},{"name":"University of Cambridge , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmaraj","family":"Durai","sequence":"additional","affiliation":[{"name":"Cardiff and Vale University Health Board , Cardiff,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Vayreda","sequence":"additional","affiliation":[{"name":"NHS Foundation Trust Guy\u2019s and St Thomas\u2019 , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurulamin M","family":"Noor","sequence":"additional","affiliation":[{"name":"Cambridge University Hospital NHS Trust , Cambridge,","place":["UK"]},{"name":"University of Cambridge , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Herath","sequence":"additional","affiliation":[{"name":"Cardiff and Vale University Health Board , Cardiff,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achini","family":"Withanachchi","sequence":"additional","affiliation":[{"name":"Cardiff and Vale University Health Board , Cardiff,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Dart","sequence":"additional","affiliation":[{"name":"NHS Foundation Trust Guy\u2019s and St Thomas\u2019 , London,","place":["UK"]},{"name":"School of Immunology and Microbial Sciences, King\u2019s College London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreedhar","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Cambridge University Hospital NHS Trust , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Parkes","sequence":"additional","affiliation":[{"name":"Cambridge University Hospital NHS Trust , Cambridge,","place":["UK"]},{"name":"University of Cambridge , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Samaan","sequence":"additional","affiliation":[{"name":"NHS Foundation Trust Guy\u2019s and St Thomas\u2019 , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Raine","sequence":"additional","affiliation":[{"name":"University of Cambridge , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M","family":"Irving","sequence":"additional","affiliation":[{"name":"NHS Foundation Trust Guy\u2019s and St Thomas\u2019 , London,","place":["UK"]},{"name":"School of Immunology and Microbial Sciences, King\u2019s College London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,19]]},"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag065\/68560432\/otag065.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag065\/68560432\/otag065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:42:32Z","timestamp":1782142952000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article\/doi\/10.1093\/crocol\/otag065\/8711827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag065","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"otag065"}}